{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T05:44:53Z","timestamp":1695879893593},"reference-count":9,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["YAKUGAKU ZASSHI"],"published-print":{"date-parts":[[2009,2,1]]},"DOI":"10.1248\/yakushi.129.241","type":"journal-article","created":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T06:00:11Z","timestamp":1233640811000},"page":"241-245","source":"Crossref","is-referenced-by-count":2,"title":["Multinational Clinical Trial in Japan and Korea on Detrusitol"],"prefix":"10.1248","volume":"129","author":[{"given":"Yukio","family":"YOSHINAGA","sequence":"first","affiliation":[{"name":"Clinical Research, Pfizer Japan Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Review Reports of New Drug Applications for Detrusitol, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, 2006 (in Japanese).<\/br> &lt;http:\/\/www.info.pmda.go.jp\/shinyaku\/g0604.html&gt;"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nilvebrant L., Hall&eacute;n B., Larsson G., <i>Life Sci.<\/i>, <b>60<\/b>, 1129-1136 (1997).","DOI":"10.1016\/S0024-3205(97)00057-X"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., Kerrebroeck P. V., Victor A., Wein A., <i>Neurourol. Urodyn.<\/i>, <b>21<\/b>, 167-178 (2002).","DOI":"10.1002\/nau.10052"},{"key":"4","unstructured":"4) Clinical Guideline for Overactive Bladder, The Neurogenic Bladder Society, 2008 (in Japanese)."},{"key":"5","unstructured":"5) Korea Food and Drug Administration Notification No. 1999-67 (in Korean)."},{"key":"6","doi-asserted-by":"publisher","unstructured":"6) Kerrebroeck P. V., Kreder K., Jonas U., Zinner N., Wein A., <i>Urology<\/i>, <b>57<\/b>, 414-421 (2001).","DOI":"10.1016\/S0090-4295(00)01113-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Homma Y., Paick J. S., Lee J. G., Kawabe K., <i>BJU Int.<\/i>, <b>92<\/b>, 741-747 (2003).","DOI":"10.1046\/j.1464-410X.2003.04468.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Joelson S., Joelson I. B., Wallander M. A., <i>Parmacoepidemiol. Drug Saf.<\/i>, <b>6 Suppl. 3<\/b>, S31-S35 (1997).","DOI":"10.1002\/(SICI)1099-1557(199710)6:3+<S31::AID-PDS288>3.3.CO;2-W"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Myrand S. P. et al, <i>Clin. Pharmacol. Ther.<\/i>, <b>84<\/b>, 347-361 (2008).","DOI":"10.1038\/sj.clpt.6100482"}],"container-title":["YAKUGAKU ZASSHI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/129\/2\/129_2_241\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T09:56:03Z","timestamp":1536400563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/129\/2\/129_2_241\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,1]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1248\/yakushi.129.241","relation":{},"ISSN":["0031-6903","1347-5231"],"issn-type":[{"value":"0031-6903","type":"print"},{"value":"1347-5231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,1]]}}}